期刊
PHARMACEUTICS
卷 14, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics14020241
关键词
EGFR; PDT; targeting; antibodies; EGF; ligands; nanobodies; affibodies; aptamers; phages
资金
- AIRC [22894]
- Italian Ministry of Economic Development
- University of Bologna
EGFR-targeted photodynamic therapy is a promising approach for cancer treatment, which selectively delivers photosensitizers to tumor environments. This review summarizes recent nanobiotechnological advancements combining photodynamic therapy with EGFR-targeted molecular cancer therapy, highlighting its advantages, drawbacks, and future perspectives.
The epidermal growth factor receptor (EGFR) plays a pivotal role in the proliferation and metastatization of cancer cells. Aberrancies in the expression and activation of EGFR are hallmarks of many human malignancies. As such, EGFR-targeted therapies hold significant potential for the cure of cancers. In recent years, photodynamic therapy (PDT) has gained increased interest as a non-invasive cancer treatment. In PDT, a photosensitizer is excited by light to produce reactive oxygen species, resulting in local cytotoxicity. One of the critical aspects of PDT is to selectively transport enough photosensitizers to the tumors environment. Accordingly, an increasing number of strategies have been devised to foster EGFR-targeted PDT. Herein, we review the recent nanobiotechnological advancements that combine the promise of PDT with EGFR-targeted molecular cancer therapy. We recapitulate the chemistry of the sensitizers and their modes of action in PDT, and summarize the advantages and pitfalls of different targeting moieties, highlighting future perspectives for EGFR-targeted photodynamic treatment of cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据